A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells

International Journal of Oncology

Volumn 48, Issue 2, 2016, Pages 734-746

  Shi, Meiyan ^a   Ren, Xia ^a   Wang, Xidi ^b   Wang, Hengxiao ^a   Liu, Guoqiang ^c   Yuan, Xiaofen ^a   Zheng, Shubo ^d   Yu, Linchang ^a   Pan, Sufei ^c   Song, Guanhua ^a   Guo, Qiang ^a   Li, Lianlian ^a   Zhang, Xiaoyu ^a   Zhang, Zhiyong ^a   Ding, Huifang ^c   Jiang, Guosheng ^a  

^a UNIVERSITY OF JINAN   (China)

^b People's Hospital of Zhangqiu City   (China)

^c Department of Otolaryngology   (China)

^d General Surgery Department   (China)

Author keywords

Apoptosis; Caspase; Leukemia; MAPK; Oridonin; Valproic acid

Indexed keywords

BETA ACTIN; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS ANTIGEN; ORIDONIN; PROTEIN BAX; PROTEIN BCL 2; VALPROIC ACID; FAS LIGAND; FASLG PROTEIN, HUMAN; KAURANE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; HL 60 CELL LINE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR CELL; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; COMBINATION DRUG THERAPY; DRUG EFFECTS; LEUKEMIA; METABOLISM; NUDE MOUSE; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; DITERPENES, KAURANE; DRUG THERAPY, COMBINATION; FAS LIGAND PROTEIN; HL-60 CELLS; HUMANS; LEUKEMIA; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; VALPROIC ACID;

EID: 84956954296     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3294     Document Type: Article

References (38)

1. Lengfelder E, Hofmann WK and Nolte F: Management of elderly patients with acute promyelocytic leukemia: Progress and problems. Ann Hematol 92: 1181-1188, 2013.
2. Chen Z, Chen GQ, Shen ZX, Chen SJ and Wang ZY: Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. Semin Hematol 38: 26-36, 2001.
3. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ and Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988.
4. Zhang L and Zhu X: Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: The experience in china. Mediterr J Hematol Infect Dis 4: e2012012, 2012.
5. Tallman MS and Nabhan C: Management of acute promyelocytic leukemia. Curr Oncol Rep 4: 381-389, 2002.
6. Douer D: Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol 107: 1-17, 2002.
7. Tallman MS, Nabhan C, Feusner JH and Rowe JM: Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 99: 759-767, 2002.
8. Sanz MA, Martín G and Lo Coco F: Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16: 433-451, 2003.
9. Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC and de Thé H: Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res 15: 6321-6326, 2009.
10. Tomita A, Kiyoi H and Naoe T: Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. Int J Hematol 97: 717-725, 2013.
11. Hillestad LK: Acute promyelocytic leukemia. Acta Med Scand 159: 189-194, 1957.
12. Liu JJ, Wu XY, Peng J, Pan XL and Lu HL: Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol 83: 691-695, 2004.
13. Gao F, Tang Q, Yang P, Fang Y, Li W and Wu Y: Apoptosis inducing and differentiation enhancement effect of oridonin on the all-trans-retinoic acid-sensitive and-resistant acute promyelocytic leukemia cells. Int J Lab Hematol 32 (1p1): e114-e122, 2010.
14. Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, et al: Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 109: 3441-3450, 2007.
15. Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, Xu MH, Wang ST, Jiang B, Liu F, et al: Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 10: 610, 2010.
16. Chen G, Wang K, Yang BY, Tang B, Chen JX and Hua ZC: Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol 40: 139-147, 2012.
17. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000.
18. Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M and Ruvolo PP: The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19: 1350-1354, 2005.
19. Phiel CJ, Zhang F, Huang EY, Guenther mg, Lazar MA and Klein PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741, 2001.
20. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, et al: Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66: 8903-8911, 2006.
21. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O and Marie JP: Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 18: 1246-1251, 2004.
22. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681, 2006.
23. Liu J, Bi G, Wen P, Yang W, Ren X, Tang T, Xie C, Dong W and Jiang G: Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol 4: 59-63, 2007.
24. Shimizu S, Narita M and Tsujimoto Y: Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483-487, 1999.
25. Constantinou C, Papas KA and Constantinou AI: Caspaseindependent pathways of programmed cell death: The unraveling of new targets of cancer therapy? Curr Cancer Drug Targets 9: 717-728, 2009.
26. Sun KW, Ma YY, Guan TP, Xia YJ, Shao CM, Chen LG, Ren YJ, Yao HB, Yang Q and He XJ: Oridonin induces apoptosis in gastric cancer through Apaf-1, cytochrome c and caspase-3 signaling pathway. World J Gastroenterol 18: 7166-7174, 2012.
27. Bao R, Shu Y, Wu X, Weng H, Ding Q, Cao Y, Li M, Mu J, Wu W, Ding Q, et al: Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer 14: 217, 2014.
28. Kawagoe R, Kawagoe H and Sano K: Valproic acid induces apoptosis in human leukemia cells by stimulating both caspasedependent and-independent apoptotic signaling pathways. Leuk Res 26: 495-502, 2002.
29. Ramos S: Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways. Mol Nutr Food Res 52: 507-526, 2008.
30. Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12: 9-18, 2002.
31. Lunghi P, Tabilio A, Dall'Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG and Bonati A: Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 17: 1783-1793, 2003.
32. Wu J, Wong WW, Khosravi F, Minden MD and Penn LZ: Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64: 6461-6468, 2004.
33. Jin S, Shen JN, Wang J, Huang G and Zhou JG: Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther 6: 261-268, 2007.
34. Wang H, Ye Y, Chui JH, Zhu GY, Li YW, Fong DW and Yu ZL: Oridonin induces G2/M cell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells. Oncol Rep 24: 647-651, 2010.
35. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
36. Henson ES and Gibson SB: Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy. Cell Signal 18: 2089-2097, 2006.
37. Bu HQ, Liu DL, Wei WT, Chen L, Huang H, Li Y and Cui JH: Oridonin induces apoptosis in SW1990 pancreatic cancer cells via p53-and caspase-dependent induction of p38 MAPK. Oncol Rep 31: 975-982, 2014.
38. Chiu CC, Chen JY, Lin KL, Huang CJ, Lee JC, Chen BH, Chen WY, Lo YH, Chen YL, Tseng CH, et al: p38 MAPK and NF-kappaB pathways are involved in naphtho[1,2-b] furan-4,5-dione induced anti-proliferation and apoptosis of human hepatoma cells. Cancer Lett 295: 92-99, 2010.